文献速递关节外科

鼻内低剂量右美托咪定减少全麻下髋关节置换术患者术后阿片类药物需求

Intranasal Low-Dose Dexmedetomidine Reduces Postoperative Opioid Requirement in Patients Undergoing Hip Arthroplasty Under General Anesthesia.
PubMed 文献 · J Arthroplasty · 2019-01-07

该回顾性研究纳入120例美国麻醉医师协会(ASA)分级1-2级、年龄35至80岁、拟在全凭静脉麻醉下接受单侧初次全髋关节置换术(THA)的患者,半数在麻醉诱导后接受50 μg鼻内右美托咪定,其余按常规处理。结果显示右美托咪定组术后累积阿片类药物需求显著降低(26.3 mg,95%CI 15.6-36.4,P < .001),术后12、24、36小时累积剂量组间已有显著差异。

要点

  • 鼻内低剂量右美托咪定组术后累积阿片类药物需求较对照组显著降低(26.3 mg,95%CI 15.6-36.4,P < .001)。
  • 术后12、24、36小时累积剂量组间差异显著(P = .01;P = .001;P < .001)。
  • 右美托咪定组麻醉恢复室平均动脉压较对照组低(P = .01),恢复室停留时间与术后住院时长组间无差异(P = .47;P = .10)。

核心结论

  • 与对照组相比,术中鼻内使用低剂量右美托咪定可降低全髋关节置换术患者术后急性期阿片类药物消耗及交感反应。

研究设计与样本

  • 回顾性研究,纳入120例美国麻醉医师协会(ASA)分级1-2级、年龄35至80岁、拟在全凭静脉麻醉下接受单侧初次全髋关节置换术的患者。
  • 半数患者在麻醉诱导后接受50 μg鼻内右美托咪定,其余患者按常规处理。
  • 术后阿片类药物需求以吗啡当量剂量计算,并评估鼻内右美托咪定对术后血流动力学及住院时长的影响。

主要发现

  • 右美托咪定组术后累积阿片类药物需求较对照组显著降低(26.3 mg,95%CI 15.6-36.4,P < .001)。
  • 术后12、24、36小时累积剂量组间差异显著(P = .01;P = .001;P < .001)。
  • 右美托咪定组麻醉恢复室平均动脉压较对照组低(P = .01)。
  • 两组麻醉恢复室停留时间及术后住院时长无差异(P = .47;P = .10)。

临床怎么用

  • 作者结论认为,与对照组相比,术中鼻内使用低剂量右美托咪定可降低全髋关节置换术患者术后急性期阿片类药物消耗及交感反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients undergoing total hip arthroplasty (THA) need substantial amount of opioids for postoperative pain management, which necessitates opioid-sparing modalities. Dexmedetomidine is a novel alpha-2-adrenoceptor-activating drug for procedural sedation. In addition to its sedative effect, dexmedetomidine has analgesic and antiemetic effects. We evaluated retrospectively the effect of intraoperatively administered intranasal low-dose dexmedetomidine on postoperative opioid requirement in patients undergoing THA. METHODS: We included 120 patients with American Society of Anesthesiologists status 1-2, age between 35 and 80 years, and scheduled for unilateral primary THA under general anesthesia with total intravenous anesthesia. Half of the patients received 50 μg of intranasal dexmedetomidine after anesthesia induction, while the rest were treated conventionally. Postoperative opioid requirements were calculated as morphine equivalent doses for both groups. The impact of intranasal dexmedetomidine on postoperative hemodynamics and length of stay was evaluated. RESULTS: The cumulative postoperative opioid requirement was significantly reduced in the dexmedetomidine group compared with the control group (26.3 mg, 95% confidence interval 15.6-36.4, P < .001). The cumulative dose was significantly different between the groups already at 12, 24, and 36 h postoperatively (P = .01; P = .001; P < .001, respectively). Dexmedetomidine group had lower mean arterial pressure in the postanesthesia care unit compared with the control group (P = .01). There was no difference in the postanesthesia care unit stay or postoperative length of stay between the two groups (P = .47; P = .10, respectively). CONCLUSION: Compared with the control group, intraoperative use of intranasal low-dose dexmedetomidine decreases opioid consumption and sympathetic response during acute postoperative period in patients undergoing THA.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Uusalo P, Jätinvuori H, Löyttyniemi E, et al. Intranasal Low-Dose Dexmedetomidine Reduces Postoperative Opioid Requirement in Patients Undergoing Hip Arthroplasty Under General Anesthesia. J Arthroplasty. 2019. PMID: 30733071. doi:10.1016/j.arth.2018.12.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。